Daraxonrasib hits the 12-month milestone in OS for the first time in #PDAC , even when given in the 2nd line.
HR 0.4! 🔥
Huge news for our patients! @OncoAlert#OncTwitter
What REALLY makes a good oncologist? in @JCO_ASCO
After 10 years and 203 JCO essays, one thing became clear: expertise alone isn’t enough.
Patient-centered care.
Clear, authentic communication.
Emotional intelligence.
And the harder work
Showing up again and again.
Openness to uncertainty.
Carrying the burden of cancer care.
Continuous growth.
Clinical competence is expected
Human connection makes the difference.
Science treats disease.
Presence treats fear.
https://t.co/g9hGjSLpGu @OncoAlert
Standing ovation for a very poignant and just beautiful opening session by @ASCOPres Dr. Lynn Schuchter “The art & science of cancer care: from comfort to cure”—it is all about our patients.
@ASCO#ASCO24
Genes that should be included in germline testing panels by tumor type (including prostate cancer): ASCO guideline just published.
https://t.co/uhbKLB8rm6
@IbrahimSahinMD1 Is in colon cancer HER2 amplification(NGS) always concordant with HER2 overexpression (IHC)? Should we test both? Different inclusion criteria used across trials, some including amplification, others not.
After 2 yrs of work,just out in @NatRevClinOncol a fully updated review on #IO in resectable #NSCLC. Proud to have worked with a stellar team,special 🙏to my genius 1st coauthor @JordiRemon, senior author @peters_solange for her wisdom and EiC @DianaNrco for her constant support